{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:25:27Z","timestamp":1749702327308,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cancers of the Vater ampulla (ampullary cancers, ACs) account for less than 1% of all gastrointestinal tumors. ACs are usually diagnosed at advanced stage, with poor prognosis and limited therapeutic options. <jats:italic>BRCA2<\/jats:italic> mutations are identified in up to 14% of ACs and, differently from other tumor types, therapeutic implications remain to be defined. Here, we report a clinical case of a metastatic AC patient in which the identification of a <jats:italic>BRCA2<\/jats:italic> germline mutation drove a personalized multimodal approach with curative-intent.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 42-year-old woman diagnosed with stage IV <jats:italic>BRCA2<\/jats:italic> germline mutant AC underwent platinum-based first line treatment achieving major tumor response but also life-threatening toxicity. Based on this, as well as on molecular findings and expected low impact of available systemic treatment options, the patient underwent radical complete surgical resection of both primary tumor and metastatic lesions. Following an isolated retroperitoneal nodal recurrence, given the expected enhanced sensitivity to radiotherapy in <jats:italic>BRCA2<\/jats:italic> mutant cancers, the patient underwent imaging-guided radiotherapy leading to long-lasting complete tumor remission. After more than 2\u00a0years, the disease remains radiologically and biochemically undetectable. The patient accessed a dedicated screening program for <jats:italic>BRCA2<\/jats:italic> germline mutation carriers and underwent prophylactic bilateral oophorectomy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Even considering the intrinsic limitations of a single clinical report, we suggest that the finding of <jats:italic>BRCA<\/jats:italic> germline mutations in ACs should be taken into consideration, together with other clinical variables, given their potential association with remarkable response to\u00a0cytotoxic chemotherapy that might be burdened with enhanced toxicity. Accordingly, <jats:italic>BRCA1\/2<\/jats:italic> mutations might offer the opportunity of personalizing treatment beyond PARP inhibitors up to the choice of a multimodal approach with curative-intent.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12957-023-02976-0","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T01:02:51Z","timestamp":1680224571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Gianluca","family":"Mauri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Patelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Roazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Rizzetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"De Carlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Cavallari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Prada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Cipani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Costanza","family":"Aquilano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Bonoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Vanzulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"doi-asserted-by":"publisher","unstructured":"Ahn DH, Bekaii-Saab T. Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book. 2014;112\u20135.\u00a0https:\/\/doi.org\/10.14694\/EdBook_AM.2014.34.112.","key":"2976_CR1","DOI":"10.14694\/EdBook_AM.2014.34.112"},{"issue":"5","key":"2976_CR2","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.3390\/curroncol28050293","volume":"28","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Dadduzio V, Lombardi L, Ricci AD, Gadaleta-Caldarola G. Ampullary carcinoma: an overview of a rare entity and discussion of current and future therapeutic challenges. Curr Oncol. 2021;28(5):3393\u2013402.","journal-title":"Curr Oncol"},{"issue":"29","key":"2976_CR3","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.2174\/0929867327666200123090153","volume":"27","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Frizziero M, McNamara MG, Valle JW. Clinical and translational research challenges in biliary tract cancers. Curr Med Chem. 2020;27(29):4756\u201377.","journal-title":"Curr Med Chem"},{"issue":"16","key":"2976_CR4","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","volume":"27","author":"MJ Overman","year":"2009","unstructured":"Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009;27(16):2598\u2013603.","journal-title":"J Clin Oncol"},{"issue":"43","key":"2976_CR5","doi-asserted-by":"publisher","first-page":"6822","DOI":"10.3748\/wjg.v26.i43.6822","volume":"26","author":"M Palmeri","year":"2020","unstructured":"Palmeri M, Funel N, Franco GD, Furbetta N, Gianardi D, Guadagni S, et al. Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology. World J Gastroenterol. 2020;26(43):6822\u201336.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"2976_CR6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.4251\/wjgo.v10.i11.370","volume":"10","author":"A Pea","year":"2018","unstructured":"Pea A, Riva G, Bernasconi R, Sereni E, Lawlor RT, Scarpa A, et al. Ampulla of Vater carcinoma: molecular landscape and clinical implications. World J Gastrointest Oncol. 2018;10(11):370\u201380.","journal-title":"World J Gastrointest Oncol"},{"issue":"7691","key":"2976_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature25475","volume":"554","author":"DM Hyman","year":"2018","unstructured":"Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189\u201394.","journal-title":"Nature"},{"issue":"10","key":"2976_CR8","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2976_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41416-019-0415-8","volume":"120","author":"G Perkins","year":"2019","unstructured":"Perkins G, Svrcek M, Bouchet-Doumenq C, Voron T, Colussi O, Debove C, et al. Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. Br J Cancer. 2019;120(7):697\u2013702.","journal-title":"Br J Cancer"},{"issue":"9","key":"2976_CR10","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/cncr.31951","volume":"125","author":"W Wong","year":"2019","unstructured":"Wong W, Lowery MA, Berger MF, Kemel Y, Taylor B, Zehir A, et al. Ampullary cancer: evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer. 2019;125(9):1441\u20138.","journal-title":"Cancer"},{"issue":"8","key":"2976_CR11","doi-asserted-by":"publisher","first-page":"e0161438","DOI":"10.1371\/journal.pone.0161438","volume":"11","author":"P Pinto","year":"2016","unstructured":"Pinto P, Peixoto A, Santos C, Rocha P, Pinto C, Pinheiro M, et al. Analysis of founder mutations in rare tumors associated with hereditary breast\/ovarian cancer reveals a novel association of BRCA2 mutations with ampulla of Vater carcinomas. PLoS ONE. 2016;11(8):e0161438.","journal-title":"PLoS ONE"},{"key":"2976_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ctrv.2018.09.002","volume":"70","author":"A Lamarca","year":"2018","unstructured":"Lamarca A, Barriuso J, McNamara MG, Valle JW. Biliary tract cancer: state of the art and potential role of DNA damage repair. Cancer Treat Rev. 2018;70:168\u201377.","journal-title":"Cancer Treat Rev"},{"issue":"18","key":"2976_CR13","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697\u2013708.","journal-title":"N Engl J Med"},{"issue":"4","key":"2976_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327.","journal-title":"N Engl J Med."},{"issue":"25","key":"2976_CR15","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med."},{"issue":"10","key":"2976_CR16","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1245\/ASO.2003.07.512","volume":"10","author":"T Todoroki","year":"2003","unstructured":"Todoroki T, Koike N, Morishita Y, Kawamoto T, Ohkohchi N, Shoda J, et al. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol. 2003;10(10):1176\u201383.","journal-title":"Ann Surg Oncol"},{"unstructured":"National Comprehensive Cancer Network. NCCN guidelines version 1.2022 for ampullary adenocarcinoma. [Internet]. NCCN. 2022 [cited 2022 Jun 18]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail.","key":"2976_CR17"},{"issue":"2","key":"2976_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pili\u00e9","year":"2019","unstructured":"Pili\u00e9 PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81\u2013104.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2976_CR19","doi-asserted-by":"publisher","first-page":"100238","DOI":"10.1016\/j.esmoop.2021.100238","volume":"6","author":"G Orsi","year":"2021","unstructured":"Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, et al. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. ESMO Open. 2021;6(5):100238.","journal-title":"ESMO Open"},{"issue":"1","key":"2976_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ygyno.2019.04.009","volume":"154","author":"F Tomao","year":"2019","unstructured":"Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, et al. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? Gynecol Oncol. 2019;154(1):138\u201343.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"2976_CR21","doi-asserted-by":"publisher","first-page":"e1471","DOI":"10.1634\/theoncologist.2019-0272","volume":"24","author":"O Weitzner","year":"2019","unstructured":"Weitzner O, Yagur Y, Kadan Y, Beiner ME, Fishman A, Ben Ezry E, et al. Chemotherapy toxicity in BRCA mutation carriers undergoing first-line platinum-based chemotherapy. Oncologist. 2019;24(12):e1471\u20135.","journal-title":"Oncologist"},{"issue":"1","key":"2976_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12029-013-9479-5","volume":"45","author":"N Aburjania","year":"2014","unstructured":"Aburjania N, Truskinovsky AM, Overman MJ, Lou E. Ampulla of Vater adenocarcinoma in a BRCA2 germline mutation carrier. J Gastrointest Cancer. 2014;45(1):87\u201390.","journal-title":"J Gastrointest Cancer"},{"issue":"4","key":"2976_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.4291","volume":"23","author":"PM Bruno","year":"2017","unstructured":"Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017;23(4):461\u201371.","journal-title":"Nat Med"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-023-02976-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-023-02976-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-023-02976-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T10:33:04Z","timestamp":1700562784000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-023-02976-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2976"],"URL":"https:\/\/doi.org\/10.1186\/s12957-023-02976-0","relation":{},"ISSN":["1477-7819"],"issn-type":[{"type":"electronic","value":"1477-7819"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"25 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient consented to provide treatments as per institutional and national guidelines. In addition, the patient consented to submission and publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"ASB is an advisory board member for Amgen, Bayer, Novartis, Sanofi, and Servier. AA is an advisory board member for Roche and Bayer and received honoraria from CheckmAb. SS is an advisory board member for Agenus, AstraZeneca, Bayer, BMS, CheckmAb, Daiichi-Sankyo, Guardant Health, Menarini, Merck, Novartis, Roche-Genentech, and Seagen. GM received honoraria from COR2ED. The remaining authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}